Femasys (FEMY)
(Delayed Data from NSDQ)
$1.20 USD
+0.08 (7.14%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.18 -0.02 (-1.67%) 6:40 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FEMY 1.20 +0.08(7.14%)
Will FEMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FEMY
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
Other News for FEMY
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Femasys Set for Growth: Buy Rating Backed by EU Regulatory Success and Strategic U.S. Expansion